Hunan Jiudian Pharmaceutical gets NMPA nod for JMHT06 clinical trials

Hunan Jiudian Pharmaceutical Co. announced today it has received a "Drug Clinical Trial Approval Notice" from the National Medical Products Administration (NMPA) for its drug candidate, JMHT06. This approval allows the company to begin clinical trials for JMHT06, a Category 2.2 chemical drug, for treating acute gouty arthritis. The drug, an external preparation, aims to offer a new treatment option for patients. The approval was granted on September 28, 2025.

The company emphasized that while this approval is a significant step, the clinical trial process, subsequent regulatory review, and market launch are subject to inherent uncertainties. The development process for JMHT06 is expected to be lengthy and capital-intensive, with potential risks related to research progress, efficacy, and market competition.

Hunan Jiudian Pharmaceutical will provide further updates on the progress of the clinical trials and product development. Investors are advised to exercise caution due to long development cycles and potential impacts of industry policies and other factors on the company's performance.